The TiTKI Project - evaluation of the risk of thrombosis associated with the use of tyrosine kinase inhibitors

Project: Research

Project Details

StatusActive
Effective start/end date1/09/15 → …

Research Output

File
  • Activities

    • 6 Oral presentation
    • 1 Invited talk

    Mécanismes thrombotiques des inhibiteurs de tyrosine kinase ciblant BCR-ABL

    Hélène Haguet (Speaker), , Jonathan Douxfils (Speaker), , François Mullier (Speaker), , Christian Chatelain (Speaker), , Carlos Graux (Speaker), & Jean-Michel Dogne (Speaker)

    21 Mar 2019

    Activity: Talk or presentation typesOral presentation

    In vitro effects of BCR-ABL TKIs on endothelial cell survival and functions

    Hélène Haguet (Speaker), , Jonathan Douxfils (Speaker), , Christian Chatelain (Speaker), , Carlos Graux (Speaker), , François Mullier (Speaker), & Jean-Michel Dogne (Speaker)

    9 Feb 2018

    Activity: Talk or presentation typesOral presentation

    Prizes

    Prix Léo Pharma Cancer & Thrombosis

    Haguet, Helene (Recipient), DOUXFILS, JONATHAN (Recipient), MULLIER, Francois (Recipient) & DOGNE, Jean-Michel (Recipient), 25 Feb 2017

    Prize: Prize (including medals and awards)

    Press / Media

    Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

    Jonathan Douxfils

    17/02/16

    1 item of Media coverage

    Press/Media: Expert Comment

    BCR-ABL TKIs May Increase Cardiovascular Risk

    Jonathan Douxfils

    16/02/16

    1 item of Media coverage

    Press/Media: Expert Comment